sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.
|
Prednisone
|
prednisolone
|
NONE
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s24
|
DDI-DrugBank.d210.s24.p0
|
Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
|
narcotic analgesics
|
antipsychotics
|
NONE
|
Hydrocodone_ddi.xml
|
DDI-DrugBank.d396.s0
|
DDI-DrugBank.d396.s0.p0
|
When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.
|
dipyridamole
|
nicardipine HCl
|
NONE
|
Nicardipine_ddi.xml
|
DDI-DrugBank.d468.s10
|
DDI-DrugBank.d468.s10.p14
|
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.
|
Physostigmine
|
alcohol
|
EFFECT
|
6536292.xml
|
DDI-MedLine.d54.s8
|
DDI-MedLine.d54.s8.p1
|
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
|
dipyridamole
|
anticoagulants
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s90
|
DDI-DrugBank.d64.s90.p21
|
As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
|
calcium channel blockers
|
verapamil
|
NONE
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s17
|
DDI-DrugBank.d269.s17.p7
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
indinavir
|
telithromycin
|
NONE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p51
|
Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
|
nelfinavir
|
combination hormonal contraceptives
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s32
|
DDI-DrugBank.d485.s32.p13
|
- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics
|
antidiabetics
|
sulfapyridine
|
EFFECT
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s37
|
DDI-DrugBank.d179.s37.p3
|
Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.
|
sucralfate
|
iron
|
NONE
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s1
|
DDI-DrugBank.d78.s1.p50
|
Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.
|
loop diuretics
|
thiazide diuretics
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s35
|
DDI-DrugBank.d558.s35.p43
|
CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.
|
Ethanol
|
ethanol
|
NONE
|
Eszopiclone_ddi.xml
|
DDI-DrugBank.d216.s0
|
DDI-DrugBank.d216.s0.p2
|
If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
|
sumatriptan
|
SSRI
|
ADVISE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s17
|
DDI-DrugBank.d568.s17.p0
|
In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.
|
quinolones
|
cyclosporine
|
MECHANISM
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s14
|
DDI-DrugBank.d78.s14.p0
|
Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.
|
Ethoxzolamide
|
tricyclics
|
EFFECT
|
Ethoxzolamide_ddi.xml
|
DDI-DrugBank.d286.s0
|
DDI-DrugBank.d286.s0.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Nizoral
|
Norvir
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p569
|
Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.
|
Aprepitant
|
midazolam
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s22
|
DDI-DrugBank.d382.s22.p4
|
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).
|
niacin
|
salbutamol
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s2
|
DDI-DrugBank.d313.s2.p18
|
Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
|
NSAIDs
|
lithium
|
MECHANISM
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s16
|
DDI-DrugBank.d210.s16.p3
|
The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.
|
anticholinergics
|
hydrocodone
|
EFFECT
|
Hydrocodone_ddi.xml
|
DDI-DrugBank.d396.s3
|
DDI-DrugBank.d396.s3.p0
|
Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
|
tolbutamide
|
tolbutamide
|
NONE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s18
|
DDI-DrugBank.d382.s18.p7
|
Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
|
lansoprazole
|
propranolol
|
NONE
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s1
|
DDI-DrugBank.d431.s1.p5
|
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.
|
doxycycline
|
nicardipine
|
NONE
|
Chlorpheniramine_ddi.xml
|
DDI-DrugBank.d235.s4
|
DDI-DrugBank.d235.s4.p50
|
Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.
|
Geocillin
|
probenecid
|
MECHANISM
|
Carbenicillin_ddi.xml
|
DDI-DrugBank.d545.s0
|
DDI-DrugBank.d545.s0.p1
|
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
|
NSAID
|
cyclosporine
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s5
|
DDI-DrugBank.d249.s5.p11
|
Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.
|
CRIXIVAN
|
delavirdine
|
ADVISE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s35
|
DDI-DrugBank.d97.s35.p0
|
Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses.
|
RR
|
InsP(3)
|
EFFECT
|
11137703.xml
|
DDI-MedLine.d114.s4
|
DDI-MedLine.d114.s4.p0
|
Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.
|
atropine sulfate
|
MAO inhibitors
|
INT
|
Diphenoxylate_ddi.xml
|
DDI-DrugBank.d538.s1
|
DDI-DrugBank.d538.s1.p3
|
If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
|
frovatriptan
|
SSRI
|
ADVISE
|
Frovatriptan_ddi.xml
|
DDI-DrugBank.d426.s4
|
DDI-DrugBank.d426.s4.p0
|
The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
|
alprazolam
|
antihistaminics
|
EFFECT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s0
|
DDI-DrugBank.d131.s0.p7
|
Amiodarone inhibits CYP2D6.
|
Amiodarone
|
CYP2D6
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s55
|
DDI-DrugBank.d143.s55.p0
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
Central Nervous System Depressants
|
skeletal muscle relaxants
|
NONE
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p10
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
diuretics
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p10
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
Duloxetine
|
TCAs
|
ADVISE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p2
|
Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
|
barbiturates
|
barbiturates
|
NONE
|
Butabarbital_ddi.xml
|
DDI-DrugBank.d184.s0
|
DDI-DrugBank.d184.s0.p50
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
ethosuximide
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p8
|
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
|
Anticonvulsants
|
ethinyl estradiol
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s12
|
DDI-DrugBank.d485.s12.p5
|
The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.
|
lymecycline
|
zinc
|
MECHANISM
|
Lymecycline_ddi.xml
|
DDI-DrugBank.d79.s0
|
DDI-DrugBank.d79.s0.p1
|
Beta-adrenergic blocking agents may also interact with sympathomimetics.
|
Beta-adrenergic blocking agents
|
sympathomimetics
|
INT
|
Azatadine_ddi.xml
|
DDI-DrugBank.d448.s4
|
DDI-DrugBank.d448.s4.p0
|
In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.
|
anticonvulsant
|
phenytoin
|
NONE
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s11
|
DDI-DrugBank.d220.s11.p3
|
Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.
|
atorvastatin
|
digoxin
|
MECHANISM
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s7
|
DDI-DrugBank.d140.s7.p3
|
These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.
|
beta-adrenergic receptor blockers
|
aspirin
|
NONE
|
Abciximab_ddi.xml
|
DDI-DrugBank.d532.s2
|
DDI-DrugBank.d532.s2.p17
|
Agents Causing Renin Release Captopril's effect will be augmented by antihypertensive agents that cause renin release.
|
Captopril
|
antihypertensive agents
|
EFFECT
|
Captopril_ddi.xml
|
DDI-DrugBank.d175.s8
|
DDI-DrugBank.d175.s8.p0
|
Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
|
Ketoconazole
|
Ketoconazole
|
NONE
|
Calcitriol_ddi.xml
|
DDI-DrugBank.d384.s8
|
DDI-DrugBank.d384.s8.p0
|
In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.
|
cimetidine
|
doxazosin
|
NONE
|
Doxazosin_ddi.xml
|
DDI-DrugBank.d367.s4
|
DDI-DrugBank.d367.s4.p3
|
Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.
|
Monoamine oxidase (MAO) inhibitors
|
antihistamines
|
EFFECT
|
Clemastine_ddi.xml
|
DDI-DrugBank.d309.s2
|
DDI-DrugBank.d309.s2.p0
|
Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)
|
clonidine
|
beta-blockers
|
ADVISE
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s7
|
DDI-DrugBank.d495.s7.p2
|
As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
|
COREG
|
verapamil
|
ADVISE
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s17
|
DDI-DrugBank.d269.s17.p5
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
ciprofloxacin
|
iron
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p16
|
The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
|
benzodiazepines
|
antihistaminics
|
EFFECT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s0
|
DDI-DrugBank.d131.s0.p3
|
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.
|
thiazide diuretics
|
beta-agonists
|
EFFECT
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s4
|
DDI-DrugBank.d284.s4.p7
|
Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.
|
ACE inhibitor
|
diuretic
|
ADVISE
|
Lisinopril_ddi.xml
|
DDI-DrugBank.d334.s4
|
DDI-DrugBank.d334.s4.p5
|
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
|
alprazolam
|
amiodarone
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s10
|
DDI-DrugBank.d131.s10.p8
|
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.
|
carbamazepine
|
tricyclic antidepressants
|
ADVISE
|
11134454.xml
|
DDI-MedLine.d36.s2
|
DDI-MedLine.d36.s2.p5
|
After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding.
|
cerulein
|
3H-spiroperidol
|
NONE
|
2857100.xml
|
DDI-MedLine.d15.s1
|
DDI-MedLine.d15.s1.p2
|
Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.
|
piperazine
|
pyrantel
|
EFFECT
|
Piperazine_ddi.xml
|
DDI-DrugBank.d326.s1
|
DDI-DrugBank.d326.s1.p7
|
Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.
|
isoniazid
|
acetaminophen
|
MECHANISM
|
Isoniazid_ddi.xml
|
DDI-DrugBank.d187.s5
|
DDI-DrugBank.d187.s5.p0
|
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
|
phenobarbital
|
corticosteroid
|
ADVISE
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s1
|
DDI-DrugBank.d487.s1.p3
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
quinidine
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p80
|
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
|
vitamin D analogues
|
Cholestyramine
|
NONE
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s0
|
DDI-DrugBank.d98.s0.p5
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
triclofos sodium
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p50
|
Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.
|
ABILIFY
|
centrally acting drugs
|
ADVISE
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s0
|
DDI-DrugBank.d509.s0.p3
|
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
|
rifampin
|
corticosteroid
|
ADVISE
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s1
|
DDI-DrugBank.d487.s1.p8
|
Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.
|
VIOXX
|
theophylline
|
ADVISE
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s28
|
DDI-DrugBank.d210.s28.p2
|
Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.
|
irbesartan
|
aliskiren
|
MECHANISM
|
Aliskiren_ddi.xml
|
DDI-DrugBank.d533.s2
|
DDI-DrugBank.d533.s2.p0
|
After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% ( 142 S.D.) and 251% ( 68 S.D.), respectively, of those obtained after co-treatment with placebo.
|
loratadine
|
loratadine
|
NONE
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s27
|
DDI-DrugBank.d458.s27.p2
|
however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.
|
ranitidine
|
ceftibuten
|
MECHANISM
|
Ceftibuten_ddi.xml
|
DDI-DrugBank.d32.s7
|
DDI-DrugBank.d32.s7.p0
|
With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions
|
dapsone
|
pyrimethamine
|
EFFECT
|
Dapsone_ddi.xml
|
DDI-DrugBank.d185.s6
|
DDI-DrugBank.d185.s6.p1
|
Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.
|
Duloxetine
|
Type 1C antiarrhythmics
|
ADVISE
|
Duloxetine_ddi.xml
|
DDI-DrugBank.d548.s9
|
DDI-DrugBank.d548.s9.p7
|
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
|
diuretics
|
prostaglandin synthetase inhibitors
|
NONE
|
Finasteride_ddi.xml
|
DDI-DrugBank.d209.s3
|
DDI-DrugBank.d209.s3.p107
|
Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.
|
rifabutin
|
CRIXIVAN
|
ADVISE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s84
|
DDI-DrugBank.d97.s84.p5
|
Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).
|
Sucralfate
|
lomefloxacin
|
MECHANISM
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s4
|
DDI-DrugBank.d516.s4.p0
|
HMG-CoA Reductase Inhibitor: atorvastatin
|
HMG-CoA Reductase Inhibitor
|
atorvastatin
|
NONE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s70
|
DDI-DrugBank.d97.s70.p0
|
Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).
|
allopurinol
|
VIDEX
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s2
|
DDI-DrugBank.d43.s2.p5
|
In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.
|
coumarin-type anticoagulants
|
Nalfon
|
EFFECT
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s8
|
DDI-DrugBank.d154.s8.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
clindamycin
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p6
|
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
|
succinylcholine
|
sodium citrate
|
NONE
|
Colistimethate_ddi.xml
|
DDI-DrugBank.d250.s2
|
DDI-DrugBank.d250.s2.p13
|
HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.
|
HMG-CoA Reductase Inhibitors
|
lovastatin
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s22
|
DDI-DrugBank.d124.s22.p0
|
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
|
Dexbrompheniramine
|
monoamine oxidase (MAO) inhibitors
|
INT
|
Dexbrompheniramine_ddi.xml
|
DDI-DrugBank.d62.s0
|
DDI-DrugBank.d62.s0.p5
|
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
|
benzodiazepines
|
antihistamines
|
EFFECT
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s1
|
DDI-DrugBank.d338.s1.p1
|
Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
|
alcohol
|
codeine
|
NONE
|
Nabilone_ddi.xml
|
DDI-DrugBank.d552.s1
|
DDI-DrugBank.d552.s1.p9
|
Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.
|
sucralfate
|
furosemide
|
EFFECT
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s10
|
DDI-DrugBank.d231.s10.p0
|
Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.
|
Nabilone
|
secobarbitone sodium
|
EFFECT
|
Nabilone_ddi.xml
|
DDI-DrugBank.d552.s1
|
DDI-DrugBank.d552.s1.p1
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
benzodiazepines
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p20
|
Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
|
Aprepitant
|
tolbutamide
|
NONE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s18
|
DDI-DrugBank.d382.s18.p5
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
alprazolam
|
Phenytoin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p118
|
Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
|
FLOLAN
|
diuretics
|
EFFECT
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s0
|
DDI-DrugBank.d241.s0.p0
|
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
fluvoxamine
|
5-HT1 agonists
|
EFFECT
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s6
|
DDI-DrugBank.d299.s6.p24
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
anesthetics
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p12
|
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.
|
phenobarbital
|
methaqualone
|
NONE
|
1109248.xml
|
DDI-MedLine.d106.s1
|
DDI-MedLine.d106.s1.p9
|
Since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions.
|
barbiturates
|
anticholinesterases
|
ADVISE
|
Atropine_ddi.xml
|
DDI-DrugBank.d222.s2
|
DDI-DrugBank.d222.s2.p0
|
Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, digoxin, or glyburide.
|
cimetidine
|
glyburide
|
NONE
|
Acitretin_ddi.xml
|
DDI-DrugBank.d353.s13
|
DDI-DrugBank.d353.s13.p4
|
Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).
|
esomeprazole
|
digoxin
|
MECHANISM
|
Esomeprazole_ddi.xml
|
DDI-DrugBank.d29.s12
|
DDI-DrugBank.d29.s12.p2
|
Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.
|
Doxorubicin
|
zalcitabine
|
EFFECT
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s25
|
DDI-DrugBank.d263.s25.p2
|
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.
|
tricyclic antidepressants
|
DILAUDID
|
EFFECT
|
Hydromorphone_ddi.xml
|
DDI-DrugBank.d26.s0
|
DDI-DrugBank.d26.s0.p32
|
PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin.
|
PGF2alpha
|
oxytocin
|
EFFECT
|
1113260.xml
|
DDI-MedLine.d17.s4
|
DDI-MedLine.d17.s4.p0
|
The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;
|
gemfibrozil
|
colestipol hydrochloride
|
MECHANISM
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s11
|
DDI-DrugBank.d345.s11.p14
|
Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
|
Isoflurane
|
NIMBEX
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s6
|
DDI-DrugBank.d60.s6.p4
|
Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).
|
Isocarboxazid
|
Antabuse
|
ADVISE
|
Isocarboxazid_ddi.xml
|
DDI-DrugBank.d108.s0
|
DDI-DrugBank.d108.s0.p0
|
In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.
|
verapamil
|
dofetilide
|
EFFECT
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s8
|
DDI-DrugBank.d558.s8.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.